{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/diverticular-disease/prescribing-information/co-amoxiclav/","result":{"pageContext":{"chapter":{"id":"524ca556-9a60-542a-9102-901470ef4882","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav","depth":2,"htmlHeader":"<!-- begin field c78cd623-3499-44c3-a758-fa5fe5c1aa9e --><h2>Co-amoxiclav</h2><!-- end field c78cd623-3499-44c3-a758-fa5fe5c1aa9e -->","summary":"","htmlStringContent":"<!-- begin item 5ca0d58a-7e2f-4f86-b0ba-b41c4af7f031 --><!-- end item 5ca0d58a-7e2f-4f86-b0ba-b41c4af7f031 -->","topic":{"id":"94c44346-c791-5b97-9e45-bacb8fe90589","topicId":"eee234d5-c667-4944-95d2-a45f5e032286","topicName":"Diverticular disease","slug":"diverticular-disease","lastRevised":"Last revised in January 2021","chapters":[{"id":"5bcd7ed5-7ab4-57a1-a517-99ee8bb7b2d5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5abc06b8-fef4-5d67-81ce-ee1c71284864","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"71ba91f6-898b-5f69-bd52-93f3b1892ad6","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"7460514b-3977-52be-9e12-06486604b194","slug":"changes","fullItemName":"Changes"},{"id":"909831b0-6f3c-5e85-8263-a5e1785b8a49","slug":"update","fullItemName":"Update"}]},{"id":"fcd203c7-5d1a-5fcc-ab90-5286ab76bd2d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2cbe6fe5-f942-566e-9136-915145ba8517","slug":"goals","fullItemName":"Goals"},{"id":"ffcabc25-6966-526d-8382-a5fcf56185ab","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"dc0b24e2-e0db-5829-baf5-a7aae6d5ab67","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b5dcfe41-ec7c-5a9f-bc96-229f8b818a77","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d9311147-ff58-5778-bb86-c0249937ef45","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"5b76632c-4924-5c26-99ab-549b62bb2f73","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"435ea69d-fb08-554b-b803-cc64d393575b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"12666ff2-dbf6-51be-b83a-78c0d4aa12e3","slug":"definition","fullItemName":"Definition"},{"id":"3a4412ce-ae17-58e7-8460-9ab759755b96","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"11908cbc-fb2b-525e-9bed-e9da60b6ad8a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"2efdd449-ac81-531a-9514-72e57632cf72","slug":"complications","fullItemName":"Complications"},{"id":"2bb98737-1604-5f47-8f96-27003159f003","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"b9740a9c-8383-57e1-8cc6-7fea164147c7","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"411e61cd-aad7-5e40-bf27-38061aae07cb","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"21f90600-3a9d-5e53-92e4-7305f17db5aa","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"c90663d3-95e7-5f18-9718-27a43a51abbf","fullItemName":"Management","slug":"management","subChapters":[{"id":"43142f56-faaf-50dc-a1b7-1d4fb26d1a5e","slug":"diverticulosis","fullItemName":"Scenario: Diverticulosis"},{"id":"a1baccf2-7945-577b-b755-eff86d33201c","slug":"diverticular-disease","fullItemName":"Scenario: Diverticular disease"},{"id":"0c23dfbe-5e71-5eeb-9b03-6b3377f49225","slug":"acute-diverticulitis","fullItemName":"Scenario: Acute diverticulitis"}]},{"id":"b30de8ba-1b8a-5f97-83ef-4d6ebc76ae50","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"2bc84877-2507-5c10-af40-fef065820ce1","slug":"bulk-forming-laxatives","fullItemName":"Bulk-forming laxatives"},{"id":"ba178fdc-1c2f-58e1-aec7-b1f903ed5207","slug":"cefalexin","fullItemName":"Cefalexin"},{"id":"524ca556-9a60-542a-9102-901470ef4882","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"463ca371-3542-5765-8350-4a0a640f0cae","slug":"ciprofloxacin","fullItemName":"Ciprofloxacin"},{"id":"231102c0-511c-5785-ac06-8720d28571cb","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"f2cde7d6-3b3a-5b9f-bf9c-9c7445a1ae6f","slug":"trimethoprim","fullItemName":"Trimethoprim"}]},{"id":"8b942243-eed9-557a-9678-01f6c77e2b91","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"7ccd6405-b8ec-557d-9d70-bce3f43accbd","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"544db73d-5bf7-5ac9-81f4-784210ec7343","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f2fb4d8d-7ad7-55ef-837b-a9faa80ba34d","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"8cbe5c96-baf1-5b25-af5c-6f36a3d9ea3c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"7518d3a3-e804-5074-908b-2b9f984cbf60","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e84d6049-8652-59d8-a02d-c49972295f21","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"1de75d4a-a4c8-5742-add9-eabcb6711bcb","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b30de8ba-1b8a-5f97-83ef-4d6ebc76ae50","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"68bdcab8-06a3-53da-9633-3280f6615f22","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 0d351b57-9482-4e62-8343-4ef790cdf256 --><h3>Contraindications and cautions</h3><!-- end field 0d351b57-9482-4e62-8343-4ef790cdf256 -->","summary":"","htmlStringContent":"<!-- begin item 526c4d73-439d-4f4e-9c14-31ddffdaeb95 --><!-- begin field 0845c116-192d-46f2-a2bd-1ee1830f83cd --><ul><li><strong>Do not prescribe co-amoxiclav to people with:</strong><ul><li>A <em>true </em>penicillin allergy — gastrointestinal adverse effects alone (for example nausea, vomiting, or diarrhoea) do <em>not </em>constitute an allergy to penicillin. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a> for more information.</li><li>A history of co-amoxiclav- or penicillin-associated jaundice or hepatic dysfunction.</li></ul></li><li><strong>Prescribe co-amoxiclav with caution to people with:</strong><ul><li>A hypersensitivity to cephalosporins.</li><li>Hepatic impairment.</li><li>Chronic kidney disease (CKD) — reduce the dose if the estimated glomerular filtration rate (eGFR) is 30 mL/minute/1.73 m<sup>2</sup> or less.</li><li>Acute lymphocytic leukaemia, chronic lymphocytic leukaemia, cytomegalovirus infection — increased risk of erythematous rashes.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/diverticular-disease/references/\">ABPI, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diverticular-disease/references/\">BNF 73, 2017</a>]</p><!-- end field 0845c116-192d-46f2-a2bd-1ee1830f83cd --><!-- end item 526c4d73-439d-4f4e-9c14-31ddffdaeb95 -->","subChapters":[]},{"id":"85971e0d-ada3-5e87-9fcf-8f22add43f18","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field df07cd60-a556-49a4-9ac7-5d3b17ccb9b4 --><h3>Adverse effects</h3><!-- end field df07cd60-a556-49a4-9ac7-5d3b17ccb9b4 -->","summary":"","htmlStringContent":"<!-- begin item f9797904-64b5-4611-9a51-b5f150d036f4 --><!-- begin field c0404707-1279-4cc3-a82a-1c8fc719d376 --><ul><li>Co-amoxiclav is usually well tolerated, but nausea, vomiting, skin rash, and diarrhoea adverse effects may occur. Advise the person that taking co-amoxiclav at the start of a meal may help reduce adverse effects and optimize absorption.<ul><li>Consider pseudomembranous colitis if a person develops severe diarrhoea during or after treatment with co-amoxiclav. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a> for more information.</li></ul></li><li>Co-amoxiclav may also cause fungal infection and vaginitis.</li><li>Anaphylaxis (delayed or immediate) is a serious but rare adverse effect of co-amoxiclav. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a> for more information.</li><li>Hepatitis and cholestatic jaundice may also occur following treatment with co-amoxiclav.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/diverticular-disease/references/\">ABPI, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diverticular-disease/references/\">BNF 73, 2017</a>]</p><!-- end field c0404707-1279-4cc3-a82a-1c8fc719d376 --><!-- end item f9797904-64b5-4611-9a51-b5f150d036f4 -->","subChapters":[]},{"id":"6b3d7848-b611-5e7f-9ded-d49543011c63","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 36eac35e-3d01-43c4-afa7-a7b300d379b5 --><h3>Drug interactions</h3><!-- end field 36eac35e-3d01-43c4-afa7-a7b300d379b5 -->","summary":"","htmlStringContent":"<!-- begin item eafe297c-2758-4695-ae70-a7b300d377a4 --><!-- begin field 6cc85f59-9a7c-4da1-9af0-a7b300d379b5 --><p><strong>Possible drug interactions with co-amoxiclav include:</strong></p><ul><li><strong>Allopurinol</strong> — be aware that concomitant use of allopurinol and amoxicillin may increase the incidence of skin rashes.</li><li><strong>Anticoagulants (for example warfarin)</strong> — prolongation of prothrombin time has been reported in people taking penicillins and warfarin concurrently.<ul><li>Monitor the prothrombin time or international normalized ratio (INR) more closely with the addition or withdrawal of a penicillin. Adjustment of the anticoagulant dose may be necessary.</li></ul></li><li><strong>Methotrexate</strong> — penicillins may reduce the excretion of methotrexate. The interaction is not usually serious and risk factors are unknown (even people on low doses of methotrexate have been affected).<ul><li>Monitor methotrexate levels more closely. One recommendation is to carry out twice weekly platelet and white cell counts for 2 weeks initially, with the measurement of methotrexate levels if toxicity is suspected.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/diverticular-disease/references/\">Baxter and Preston, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diverticular-disease/references/\">ABPI, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diverticular-disease/references/\">BNF 73, 2017</a>]</p><!-- end field 6cc85f59-9a7c-4da1-9af0-a7b300d379b5 --><!-- end item eafe297c-2758-4695-ae70-a7b300d377a4 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}